Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study

• Published in: Lupus science & medicine Vol. 9; no. 1; p. e000617
• Main Authors: Jiang, Nan, Li, Mengtao, Zhang, Hongfeng, Duan, Xinwang, Li, Xiaofeng, Fang, Yongfei, Li, Hongbin, Yang, Pingting, Luo, Hui, Wang, Yanhong, Peng, Liying, Zhao, Jiuliang, Wu, Chanyuan, Wang, Qian, Tian, Xinping, Zhao, Yan, Zeng, Xiaofeng
• Format: Journal Article
• Language: English
• Published: England Lupus Foundation of America 01.01.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: autoimmune diseases; Clinical Trials and Drug Discovery; Cohort analysis; Cohort Studies; Drug dosages; Humans; Immunosuppressive agents; Immunosuppressive Agents - adverse effects; Lupus; lupus erythematosus; Lupus Erythematosus, Systemic - drug therapy; Remission (Medicine); Rheumatology; Sirolimus - adverse effects; systemic; Tacrolimus - adverse effects; therapeutics; Variables; China; autoimmune diseases; systemic; therapeutics; lupus erythematosus

ObjectiveThe effectiveness and safety of sirolimus for SLE treatment have been shown in some uncontrolled studies. However, a comparison of sirolimus with other classic immunosuppressants has not been reported. We conducted the study to compare the effectiveness and safety of sirolimus versus tacrol...